Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials

Ashley Wilder Smith; Lisa Dimartino; Sofia F. Garcia; Sandra A. Mitchell; Kathryn J. Ruddy; Justin D. Smith; Sandra L. Wong; September Cahue; David Cella; Roxanne E. Jensen; Michael J. Hassett; Christine Hodgdon; Barbara Kroner; Raymond U. Osarogiagbon; Jennifer Popovic; Kimberly Richardson; Deborah Schrag; Andrea L. Cheville

doi:10.1093/jncics/pkad073

Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials

Ashley Wilder Smith, Lisa Dimartino, Sofia F. Garcia, Sandra A. Mitchell, Kathryn J. Ruddy, Justin D. Smith, Sandra L. Wong, September Cahue, David Cella, Roxanne E. Jensen, Michael J. Hassett, Christine Hodgdon, Barbara Kroner, Raymond U. Osarogiagbon, Jennifer Popovic, Kimberly Richardson, Deborah Schrag, Andrea L. Cheville

Research output: Contribution to journal › Review article › peer-review

Abstract

Cancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium's conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.

Original language	English (US)
Article number	pkad073
Journal	JNCI Cancer Spectrum
Volume	7
Issue number	6
DOIs	https://doi.org/10.1093/jncics/pkad073
State	Published - Dec 1 2023

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/jncics/pkad073

Cite this

Smith, A. W., Dimartino, L., Garcia, S. F., Mitchell, S. A., Ruddy, K. J., Smith, J. D., Wong, S. L., Cahue, S., Cella, D., Jensen, R. E., Hassett, M. J., Hodgdon, C., Kroner, B., Osarogiagbon, R. U., Popovic, J., Richardson, K., Schrag, D., & Cheville, A. L. (2023). Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials. JNCI Cancer Spectrum, 7(6), Article pkad073. https://doi.org/10.1093/jncics/pkad073

Smith, AW, Dimartino, L, Garcia, SF, Mitchell, SA, Ruddy, KJ, Smith, JD, Wong, SL, Cahue, S, Cella, D, Jensen, RE, Hassett, MJ, Hodgdon, C, Kroner, B, Osarogiagbon, RU, Popovic, J, Richardson, K, Schrag, D & Cheville, AL 2023, 'Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials', JNCI Cancer Spectrum, vol. 7, no. 6, pkad073. https://doi.org/10.1093/jncics/pkad073

@article{25a571fd00f548d381196bee15577403,

title = "Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials",

abstract = "Cancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium's conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.",

author = "Smith, {Ashley Wilder} and Lisa Dimartino and Garcia, {Sofia F.} and Mitchell, {Sandra A.} and Ruddy, {Kathryn J.} and Smith, {Justin D.} and Wong, {Sandra L.} and September Cahue and David Cella and Jensen, {Roxanne E.} and Hassett, {Michael J.} and Christine Hodgdon and Barbara Kroner and Osarogiagbon, {Raymond U.} and Jennifer Popovic and Kimberly Richardson and Deborah Schrag and Cheville, {Andrea L.}",

note = "Publisher Copyright: {\textcopyright} 2023 Published by Oxford University Press.",

year = "2023",

month = dec,

day = "1",

doi = "10.1093/jncics/pkad073",

language = "English (US)",

volume = "7",

journal = "JNCI Cancer Spectrum",

issn = "2515-5091",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Systematic symptom management in the IMPACT Consortium

T2 - rationale and design for 3 effectiveness-implementation trials

AU - Smith, Ashley Wilder

AU - Dimartino, Lisa

AU - Garcia, Sofia F.

AU - Mitchell, Sandra A.

AU - Ruddy, Kathryn J.

AU - Smith, Justin D.

AU - Wong, Sandra L.

AU - Cahue, September

AU - Cella, David

AU - Jensen, Roxanne E.

AU - Hassett, Michael J.

AU - Hodgdon, Christine

AU - Kroner, Barbara

AU - Osarogiagbon, Raymond U.

AU - Popovic, Jennifer

AU - Richardson, Kimberly

AU - Schrag, Deborah

AU - Cheville, Andrea L.

PY - 2023/12/1

Y1 - 2023/12/1

N2 - Cancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium's conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.

AB - Cancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium's conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.

UR - http://www.scopus.com/inward/record.url?scp=85177494529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85177494529&partnerID=8YFLogxK

U2 - 10.1093/jncics/pkad073

DO - 10.1093/jncics/pkad073

M3 - Review article

C2 - 37930033

AN - SCOPUS:85177494529

SN - 2515-5091

VL - 7

JO - JNCI Cancer Spectrum

JF - JNCI Cancer Spectrum

IS - 6

M1 - pkad073

ER -

Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this